Changeflow GovPing Healthcare & Life Sciences Chimeric Klebicins - Bactoclear Holdings
Priority review Rule Added Final

Chimeric Klebicins - Bactoclear Holdings

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO granted US Patent 12,606,598B2 to Bactoclear Holdings PTE, Ltd. covering chimeric klebicins — engineered antimicrobial proteins combining translocation, receptor-binding, and bactericidal domains from different klebicin sources. The patent includes 15 claims and covers compositions, kits, and methods of use designed to improve target cell range and bactericidal activity against bacterial pathogens.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued Patent 12,606,598B2 for chimeric klebicins to Bactoclear Holdings PTE, Ltd., covering a class of engineered antimicrobial proteins that combine functional domains from multiple klebicin sources to broaden target cell range and enhance bactericidal activity. The patent protects the compositions, kits, and methods of use disclosed.

Pharmaceutical and biotechnology companies developing antimicrobial or protein-based therapeutics should review this grant to assess freedom-to-operate in the klebicin space. Competitors pursuing similar domain-shuffling approaches to bactericidal proteins may need to evaluate potential infringement exposure or explore licensing arrangements with the assignee.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Chimeric klebicins

Grant US12606598B2 Kind: B2 Apr 21, 2026

Assignee

Bactoclear Holdings PTE, Ltd.

Inventors

Anisha Ambady, Chemira Biddappa Appaiah, Vivek Daniel Paul, R. Sanjeev Saravanan, Keerthana Anbalagan

Abstract

The present invention provides chimeric klebicins by combining translocation, receptor-binding, and bactericidal domains originated from different klebicins to achieve improved target cell range and bactericidal activity. Also provided are related compositions, kits, and methods of use of these chimeric klebicins.

CPC Classifications

C07K 14/26 C07K 2319/00 A61K 9/0019 A61K 9/0073 A61K 38/164 A61P 31/04

Filing Date

2022-07-08

Application No.

17811492

Claims

15

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
US12606598B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant Biotechnology IP Antimicrobial research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!